Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nathanael Gray
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Petra Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
NA
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
Worldwide, lung cancer is the leading cancer killer accounting for 1.37 million deaths annually. Lung cancer arises as a result of environmental exposures, such as smoking, combined with genetic alterations such as deregulation or loss of key proteins that control cell growth. One protein that is frequently lost in many cancers, including lung cancer, is p53. The loss of p53 makes it easier for precancerous cells to progress to a cancerous state. We have discovered that the loss of p53 makes cancer cells uniquely vulnerable to drugs that disable another protein called PIP4K2. The goal of this research proposal is to develop and investigate whether prototype drugs targeting PIP4K2 will work in preclinical models of p53 deficient lung cancer. This research will serve to validate whether PIP4K2 is indeed a promising drug target and will provide starting points for drugs that can be advanced into clinical trials.
Filed on July 10, 2018.
Tell us what you know about Nathanael Gray's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nathanael Gray filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $100,000 - $149,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.